Effect of haloperidol on mPer1 gene expression in mouse suprachiasmatic nuclei.
The effect of a typical neuroleptic haloperidol (Hal) on mPer1 gene expression was investigated in mouse suprachiasmatic nuclei (SCN). Hal induced mPer1 mRNA levels both in vivo and in cultured SCN cells. For mechanisms underlying Hal-induced mPer1 expression, N-methyl-d-aspartate (NMDA) glutamate receptor subtype, the phosphorylation form of the transcription factor, and the Ser-133 phosphorylation form of cAMP-responsive element-binding protein (CREB) played an important role, because the induction of mPer1 mRNA significantly decreased after pretreatment with a non-competitive NMDA receptor antagonist, such as MK-801 or CREB antisense. These results suggest that Hal may increase CREB phosphorylation and mPer1 expression according to the activation of the NMDA receptor through the dopaminergic pathways. Although the injection of Hal during the light period increased the amplitude of mPer1 mRNA rhythmicity in a nondrug state, the injection of the drug during the dark period disturbed the rhythmic pattern of mPer1 mRNA. These results suggest that the rhythmicity of clock genes in SCN may be disturbed depending on the dosing time of Hal. On the other hand, because the induction of mPer1 mRNA by Hal seems to be at least partly caused by the NMDA receptor, showing a phase shift or resetting effect of the circadian clock, Hal may also cause such phase shift effects.
Viyoch
Jarupa
J
Clinical Pharmacokinetics, Division of Clinical Pharmacy, Department of Medico-Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Matsunaga
Naoya
N
Yoshida
Miyako
M
To
Hideto
H
Higuchi
Shun
S
Ohdo
Shigehiro
S
D000818:Animals; D018797:Cell Cycle Proteins; D002478:Cells, Cultured; D002940:Circadian Rhythm; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D005786:Gene Expression Regulation / Q000187:drug effects*; D006220:Haloperidol / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D009687:Nuclear Proteins / Q000235:genetics*; D056950:Period Circadian Proteins; D010766:Phosphorylation; D012333:RNA, Messenger / Q000032:analysis; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D013493:Suprachiasmatic Nucleus / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects
D018797:Cell Cycle Proteins; D017362:Cyclic AMP Response Element-Binding Protein; D018492:Dopamine Antagonists; D009687:Nuclear Proteins; C539023:Per1 protein, mouse; D056950:Period Circadian Proteins; D012333:RNA, Messenger; D016194:Receptors, N-Methyl-D-Aspartate; D006220:Haloperidol